JOHN L. ZABRISKIE, PH.D. - Corporate Board Profile

Oruka Therapeutics, Inc.

Filing Date	Source Excerpt
2009-04-30	John L. Zabriskie, Ph.D. Dr. Zabriskie has served as a member of the Company 2 Board of Directors since our merger with ARCA Colorado. Before the merger, Dr. Zabriskie had served as a director of ARCA Colorado since March 2005. Dr. Zabriskie is Co-Founder and Director of Puretech Ventures, LLC, and the past Chairman of the Board, Chief Executive Officer, and President of NEN Life Science Products, Inc.
2010-04-07	Dr. Zabriskie, age 70, has served as a member of the Company 27s Board of Directors since the merger. ... Dr. Zabriskie is an appropriate nominee to the Company 27s Board of Directors due to his extensive experience in the pharmaceutical industry, including senior management experience up to the level of president and chief executive officer of significant public companies, as well as his experience on the boards of directors of public companies, including service on audit committees. Dr. Zabriskie also has extensive experience with and knowledge of the Company 27s business from his service on the Board of ARCA Colorado since 2005, and his service as a Board member and Chairman of the Audit Committee of the Company since January 2009.
2011-03-30	Dr. Zabriskie, age 71, has served as a member of the Company 27s Board of Directors since the merger with Nuvelo in January 2009. ... Dr. Zabriskie also has extensive experience with and knowledge of the Company 27s business from his service on the Board of ARCA Colorado since 2005, and his service as a Board member and Chairman of the Audit Committee of the Company since January 2009. ... The following table shows for the fiscal year ended December 31, 2010 certain information with respect to the compensation of all non-employee directors of the Company: ... John L. Zabriskie, Ph.D. 45,000 6,435 51,435.
2012-04-05	Dr. Zabriskie, age 72, has served as a member of the Companys Board of Directors since the merger with Nuvelo in January 2009. ... Dr. Zabriskie also has extensive experience with and knowledge of the Companys business from his service on the Board of ARCA Colorado since 2005, his service as a Board member and Chairman of the Audit Committee of the Company since January 2009, and his service as a member of the Compensation Committee since March 2011. ... The Audit Committee is composed of three directors: Dr. Zabriskie (chair), Dr. Grais, and Dr. Sobel. ... Dr. Zabriskie was elected to serve on the Compensation Committee effective March 29, 2011. ... Director Compensation for fiscal 2011 shows John L. Zabriskie, Ph.D. with total compensation of $57,500.
2013-02-01	John L. Zabriskie, Ph.D. is listed as a director with beneficial ownership of 289,059 shares. No specific age, committees, or compensation details are provided.
2013-08-01	Dr. Zabriskie, age 74, has served as a member of the Company 27s Board of Directors since the merger with Nuvelo in January 2009. ... Dr. Zabriskie is an appropriate nominee to the Company 27s Board of Directors due to his extensive experience in the pharmaceutical industry, including senior management experience up to the level of president and chief executive officer of significant public companies, as well as his experience on the boards of directors of public companies, including service on audit committees. Dr. Zabriskie also has extensive experience with and knowledge of the Company 27s business from his service on the Board of ARCA Colorado since 2005, his service as a Board member and Chairman of the Audit Committee of the Company since January 2009, and his service as a member of the Compensation Committee since March 2011. ... The Audit Committee is currently composed of two directors: Dr. Zabriskie (chair) and Dr. Grais, as a result of the death of the third member in May, 2013. ... The Compensation Committee is currently composed of two directors: Dr. Linda Grais (chair) and Dr. Raymond Woosley. ... The Nominating and Corporate Governance Committee is currently composed of two directors, Dr. Grais and Dr. Woosley. ... The following table shows for the fiscal year ended December 31, 2012 certain information with respect to the compensation of all non-employee directors of the Company: ... John L. Zabriskie, Ph.D. Fees Earned or Paid in Cash ($) 26,250, Option Awards ($) 5,457, Total ($) 31,707.